News

The company states LYNX is the world’s first and only pattern scanning laser indirect ophthalmoscope and is battery-powered to provide surgeons with an untethered laser solution.

The investigators found that the premature births to be associated with vascular changes on ocular coherence tomography-angiography.

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical characteristics of choroidal metastasis in this patient population and report treatment outcomes after targeted therapy compared with conventional radiotherapy and/or chemotherapy.

The “Triangle sign” seen on ultrasound is a “distinctive and reliable” ultrasound feature for differentiating total choroidal detachments and suprachoroidal hemorrhages.

Funds from the Inasmuch Foundation and The Samuel Roberts Noble Foundation will support the purchase of equipment, including computerized eye simulators, a laser injector, and a device for measuring the electrical resistance of cells.

The meetings support the company’s submission for its bioengineered corneal implants to eliminate corneal blindness.

Chen and colleagues conducted a longitudinal study that included patients with high myopia who were followed for 10 years. Detailed ophthalmic examinations were conducted at the baseline and follow-up visits that included measurements of the BCVA and visual fields in 568 eyes of 284 patients.

The NeurEYE research team will use millions of eye scans from Scottish optometrists to create the data set.

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

ARCATUS or ARVN001, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries is formally known as XIPERE in the United States and was developed by Clearside Biomedical.

The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa.

Topline data results are expected in February 2025.

Changes can result in bacterial contamination, loss of drug activity, and inflammation

Following the switch from multifocal to single-vision contact lenses, axial elongation increased by 0.03 mm/year, and myopia progressed at a rate of −0.17 D annually after switching to single-vision lenses.

Linsitinib is being evaluated in patients with active, moderate to severe thyroid eye disease (TED).

Andrew G. Lee, MD, and Drew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve can swell, focusing on the condition of papilledema caused by elevated intracranial pressure.

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

RayTrace has been utilized globally by surgeons since 2008.

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease.

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in 3 cohorts.

Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky.

Cost among other factors may deter patients from screening, especially in rural and low-resource settings.

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics License Application in the first quarter of 2025.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Study sees a positive association between the dietary inflammatory index (DII) and non-refractive visual impairment among US populations

This trial is designed to evaluate 4D-150 in diabetic macular edema.

The funding will support activities like formal pharmacology and toxicology testing.

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME